A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant.

A Phase-1, 6-Month Open-Label, Dose-Ranging Pharmacokinetic Study in Stabilized Patients with Schizophrenia Following Risperidone Implant. Psychopharmacol Bull. 2017 Sep 15;47(4):29-35 Authors: Dammerman R, Kim S, Adera M, Schwarz A PMID: 28936006 [PubMed - in process]
Source: Psychopharmacology Bulletin - Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research